Viking Therapeutics (VKTX) Research & Development (2014 - 2026)
Viking Therapeutics (VKTX) recorded Research & Development of $115.75 million in Q2 2026, up 92.4% from $60.15 million a year earlier but down 22.9% from the prior quarter.
Powered by 
Analysis
Viking Therapeutics (VKTX) Research & Development (2014 - 2026) Analysis & Trends
On a TTM basis, Viking Therapeutics' Research & Development came in at $509.32 million as of Jun 30, 2026, up 227.9% year-over-year; for FY2025, it was $344.96 million, up 239.4% from FY2024.
- Annual Research & Development has increased for ten straight years, with a five-year compound annual growth rate of 61.0% (FY2020 to FY2025).
- Across earlier years, Research & Development came in at $101.64 million in FY2024 (+59.3%), $63.81 million in FY2023 (+17.6%), $54.23 million in FY2022 (+20.6%) and $44.98 million in FY2021 (+40.9%).
- Quarterly Research & Development has ranged from $9.85 million in Q4 2021 to $153.46 million in Q4 2025 over the past five years.
- On a year-over-year basis, Research & Development has increased for 13 consecutive quarters, with growth averaging 168.1% over the last eight quarters.
- Peak year-over-year performance for Research & Development in the last five years was growth of 395.2% in Q4 2025, against a decline of 12.3% in Q1 2023 at the low end.
- Per Business Quant, the preceding three quarters came in at $150.15 million (Q1 2026), $153.46 million (Q4 2025) and $89.95 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,136.97 Bn | 1,105.55 Bn | 19.71 Bn | 3.82 Bn |
| 2 | Johnson & Johnson | 619.72 Bn | 538.25 Bn | 17.26 Bn | 3.65 Bn |
| 3 | AbbVie | 503.40 Bn | 476.52 Bn | 12.70 Bn | 2.34 Bn |
| 4 | Merck | 370.15 Bn | 324.53 Bn | 12.21 Bn | 9.74 Bn |
| 5 | Novartis Ag | 298.64 Bn | 262.63 Bn | 11.24 Bn | 2.85 Bn |
| 6 | Astrazeneca | 261.07 Bn | 234.76 Bn | 12.86 Bn | 4.05 Bn |
| 7 | Amgen | 237.00 Bn | 192.40 Bn | 7.24 Bn | 1.87 Bn |
| 8 | Gilead Sciences | 191.24 Bn | 165.43 Bn | 6.22 Bn | 1.76 Bn |
| 9 | Pfizer | 170.31 Bn | 116.96 Bn | 10.94 Bn | 2.81 Bn |
| 10 | Viking Therapeutics | 3.07 Bn | 545.20 Mn | - | 115.75 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 115.75 Mn |
| Mar 31, 2026 | 150.15 Mn |
| Dec 31, 2025 | 153.46 Mn |
| Sep 30, 2025 | 89.95 Mn |
| Jun 30, 2025 | 60.15 Mn |
| Mar 31, 2025 | 41.39 Mn |
| Dec 31, 2024 | 30.99 Mn |
| Sep 30, 2024 | 22.79 Mn |
| Jun 30, 2024 | 23.77 Mn |
| Mar 31, 2024 | 24.10 Mn |
| Dec 31, 2023 | 20.50 Mn |
| Sep 30, 2023 | 18.38 Mn |
| Jun 30, 2023 | 13.92 Mn |
| Mar 31, 2023 | 11.01 Mn |
| Dec 31, 2022 | 16.18 Mn |
| Sep 30, 2022 | 11.96 Mn |
| Jun 30, 2022 | 13.54 Mn |
| Mar 31, 2022 | 12.56 Mn |
| Dec 31, 2021 | 9.85 Mn |
| Sep 30, 2021 | 10.80 Mn |
API Access
Viking Therapeutics Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=VKTX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "VKTX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=VKTX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();